# [11C]Cimbi-36 Dosimetry

> **NCT02629003** · PHASE1 · COMPLETED · sponsor: **Gitte Moos Knudsen** · enrollment: 8 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** [11C]Cimbi-36
- **DRUG:** [11C]Cimbi-36-5

## Key facts

- **NCT ID:** NCT02629003
- **Lead sponsor:** Gitte Moos Knudsen
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2018-10-10
- **Final completion:** 2018-10-10
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2019-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02629003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02629003, "[11C]Cimbi-36 Dosimetry". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02629003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*